Used in research to inhibit PI3Kβ (phosphoinositide 3-kinase beta), AZD6482 helps study signaling pathways involved in cancer and thrombosis. It shows potential in reducing tumor cell growth and platelet aggregation, making it a tool compound for exploring treatments in oncology and cardiovascular diseases. Its selectivity for PI3Kβ allows scientists to investigate the specific role of this isoform in cellular functions and disease models.